Graft-versus-host disease primary prevention: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) |
mNo edit summary |
||
| Line 17: | Line 17: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[Category:Primary care]] | [[Category:Primary care]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Immunology]] | ||
Revision as of 16:08, 17 June 2016
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease primary prevention On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease primary prevention |
|
Risk calculators and risk factors for Graft-versus-host disease primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Primary Prevention
- DNA-based tissue typing allows for more precise HLA matching between donors and transplant patients, which has been proven to reduce the incidence and severity of GVHD and to increase long-term survival.[1].
- The T-cells of umbilical cord blood (UCB) have an inherent immunological immaturity[2], and the use of UCB stem cells in unrelated donor transplants has a reduced incidence and severity of GVHD[3].
- Methotrexate, cyclosporin A and tacrolimus are common drugs used for GVHD prophylaxis.
- Graft-versus-host-disease can largely be avoided by performing a T-cell depleted bone marrow transplant. However these types of transplants come at a cost of diminished graft-versus-tumor effect, greater risk of engraftment failure or cancer relapse[4], and general immunodeficiency, resulting in a patient more susceptible to viral, bacterial, and fungal infection. In a multi-center study, disease-free survival at 3 years was not different between T cell depleted and T cell replete transplants[5].
References
- ↑ Morishima Y, Sasazuki T, Inoko H; et al. (2002). "The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors". Blood. 99 (11): 4200–6. PMID 12010826.
- ↑ Grewal SS, Barker JN, Davies SM, Wagner JE (2003). "Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?". Blood. 101 (11): 4233–44. doi:10.1182/blood-2002-08-2510. PMID 12522002.
- ↑ Laughlin MJ, Barker J, Bambach B; et al. (2001). "Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors". N. Engl. J. Med. 344 (24): 1815–22. PMID 11407342.
- ↑ Hale G, Waldmann H (1994). "Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases". Bone Marrow Transplant. 13 (5): 597–611. PMID 8054913.
- ↑ Lancet 2005 Aug 27-Sep 2;366(9487):733-41